Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer.
Interleukin-2 (IL-2) was detected in urine but not serum of patients receiving intravesical bacille Calmette-Guerin (BCG) therapy for bladder cancer. IL-2 activity was neutralized by anti-IL-2 antibody. No IL-2 was detected in urine before BCG therapy or from control donors. BCG-induced urine IL-2 peaked 4-8 hr after treatment but was rarely observed after 24 hr. The presence of BCG-induced lymphokines may be associated with antitumor activity.
D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000628:therapy* / Q000652:urine; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis* / Q000652:urine; D008222:Lymphokines / Q000096:biosynthesis; D001743:Urinary Bladder; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000628:therapy* / Q000652:urine
D001500:BCG Vaccine; D007376:Interleukin-2; D008222:Lymphokines